News

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology…

10 months ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25…

10 months ago

LifeMD to Report Fourth Quarter 2024 Financial Results on March 10

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,…

10 months ago

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference

ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…

10 months ago

Nkarta to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural…

10 months ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure…

10 months ago

Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference

BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early…

10 months ago

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LONDON--(BUSINESS WIRE)--#cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year…

10 months ago

Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025

Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million Full Year 2024…

10 months ago

Edison Issues Report on Accsys Technologies (AXS)

London, United Kingdom--(Newsfile Corp. - February 25, 2025) - Edison issues report on Accsys Technologies (AIM: AXS).At its investor strategy…

10 months ago